Targanta shifts R&D focus, reduces burn rate

Guest Contributor
February 22, 2005

Montreal’s Targanta Therapeutics Inc has initiated a restructuring plan that will see a shift away from discovery research to the pre-clinical development of potential products and the termination of nine of its 42 employees. The move comes just weeks after its appointment of Dr Thomas Parr as its new chief scientific officer. Targanta’s burn rate will also be significantly reduced while biology resources are being redirected to support its chemistry group....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.